We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An item in yesterday’s Device Daily Bulletin incorrectly listed what Cerus’ Intercept blood system was approved for. It received approval for the ex vivo preparation of whole blood-derived and apheresis plasma to minimize the risk of transfusion-transmitted infections.